# Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

> **NCT03712345** · PHASE2 · TERMINATED · sponsor: **InflaRx GmbH** · enrollment: 20 (actual)

## Conditions studied

- Granulomatosis With Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)

## Interventions

- **DRUG:** IFX-1 low dose
- **DRUG:** IFX-1 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03712345
- **Lead sponsor:** InflaRx GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-15
- **Primary completion:** 2020-09-10
- **Final completion:** 2021-05-03
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Due to COVID-19 pandemic outbreak and its impact on overall study activities. All efforts were made to ensure that participants that were enrolled and/or were still in the study will continue to receive treatment and follow-up until study completion.
- **Last updated:** 2022-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03712345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03712345, "Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03712345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*